公开(公告)号：KR1020140049414A

公开(公告)日：2014-04-25

申请号：KR1020120115649

申请日：2012-10-17

Applicant: 성균관대학교산학협력단

Inventor： 조동규 ,  박종성 ,  김학균 ,  반가히 ,  조윤석 ,  최보윤

IPC: C12N15/85 ,  C12N5/10 ,  G01N33/52

Abstract: The present invention relates to a cell line expressing a β-secretase 1 (BACE1) promoter-fluorescent protein fusion reporter gene and a method for screening a drug regulating the expression of BACE1 using the same, and more specifically, to a cell line stably expressing a reporter gene in which a fluorescent protein is fused to a promoter gene of the BACE1 enzyme of synthesizing an amyloid β-protein, which is a cause of Alzheimer dementia, and a method for screening a material having a therapeutic effect by applying a drug candidate agent against Alzheimer dementia to the cell line. The existing drugs against Alzheimer dementia were mainly inhibitors that directly regulate activity of the BACE1 enzyme, but the regulation of BACE1 expression itself is being recognized to be more effective and fundamental treatment. Further, BACE1 is an enzyme that has been known to be overexpressed in obesity and diabetes. The cell line and the screening method using the same according to the present invention are expected to be importantly applicable in screening multiple drug candidates against Alzheimer dementia, obesity, or diabetes, which inhibit the expression of BACE1, at low costs and for a short period of time. [Reference numerals] (AA) BASE 1 promoter activity reduction

Abstract translation: 本发明涉及一种表达β-分泌酶1（BACE1）启动子 - 荧光蛋白融合报告基因的细胞系，以及使用该基因筛选调节BACE1表达的药物的方法，更具体地说，涉及稳定表达 其中荧光蛋白与合成淀粉样蛋白β-蛋白的BACE1酶的启动子基因融合的报告基因，其是阿尔茨海默氏痴呆的原因，以及通过应用候选药物筛选具有治疗效果的材料的方法 对阿尔茨海默氏痴呆的药物进入细胞系。 目前针对阿尔茨海默氏痴呆的药物主要是直接调节BACE1酶活性的抑制剂，但BACE1表达本身的调控被认为是更有效和最根本的治疗方法。 此外，BACE1是已知在肥胖和糖尿病中过表达的酶。 预期根据本发明的细胞系和使用其的筛选方法重要地可用于以低成本和短时间筛选抑制BACE1表达的阿尔茨海默氏痴呆，肥胖症或糖尿病的多种药物候选物 的时间。 （参考号）（AA）BASE1启动子活性降低